Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.
D. A. Bota
No relevant relationships to disclose
Z. Eroglu
No relevant relationships to disclose
D. A. Reardon
No relevant relationships to disclose
B. D. Fu
No relevant relationships to disclose
J. Norfleet
No relevant relationships to disclose
A. Desjardins
No relevant relationships to disclose
M. E. Linskey
No relevant relationships to disclose
K. Peters
No relevant relationships to disclose
H. S. Friedman
No relevant relationships to disclose
J. J. Vredenburgh
No relevant relationships to disclose